Peptide modulators of angiogenesis and use thereof
AssigneeThe Johns Hopkins University
InventorsAleksander S. Popel, Emmanouil D. Karagiannis
Life of this patent
Estimating the term…
Abstract
The invention generally features compositions and methods that are useful for modulating blood vessel formation, as well as methods that provide for the systematic and efficient identification of angiogenesis modulators. As described in more detail below, a systematic computational methodology based on bioinformatics was used to identify novel peptide modulators of angiogenesis that have been characterized in vitro and/or in vivo.
Claims56
An isolated peptide or analog thereof comprising one of the following amino acid sequences:
- (SEQ ID NO:
- 2287)
- TSP Motif:
- W-X(2)-C-X(3)-C-X(2)-G,
- CXC Motif:
- G-X(3)-C-L
- (SEQ ID NO:
- 2288)
- Collagen Motif:
- C-N-X(3)-V-C
- Collagen Motif:
- P-F-X(2)-C
- (SEQ ID NO:
- 2289)
- Somatotropin Motif:
- L-X(3)-L-L-X(3)-S-X-L
- (SEQ ID NO:
- 2290)
- Serpin Motif:
- L-X(2)-E-E-X-P
- wherein X denotes a variable amino acid and the number in parentheses denotes the number of variable amino acids;
- W denotes tryptophan;
- C denotes cysteine, G denotes glycine, V denotes valine;
- L denotes leucine, P is proline, and wherein the peptide reduces blood vessel formation in a cell, tissue or organ.
An isolated peptide or analog thereof having at least 85% identity to an amino acid sequence shown in Table 1-10.
An isolated peptide or analog thereof comprising or consisting essentially of a sequence having at least 85% amino acid sequence identity to an amino acid sequence selected from the group consisting of:
- (SEQ ID NO:
- 2291)
- Placental Lactogen
- LLRISLLLIESWLE
- (SEQ ID NO:
- 2292)
- hGH-V
- LLRISLLLTQSWLE
- (SEQ ID NO:
- 2293)
- GH2
- LLHISLLLIQSWLE
- (SEQ ID NO:
- 2294)
- Chorionic somatomammotropin
- LLRLLLLIESWLE
- (SEQ ID NO:
- 2295)
- Chorionic somatomammotropin
- LLHISLLLIESRLE
- hormone-like 1
- (SEQ ID NO:
- 2296)
- Transmembrane protein 45A
- LLRSSLILLQGSWF
- (SEQ ID NO:
- 2297)
- IL-17 receptor C
- RLRLLTLQSWLL
- (SEQ ID NO:
- 2298)
- Neuropeptide FF receptor 2
- LLIVALLFILSWL
- (SEQ ID NO:
- 2299)
- Brush border myosin-I
- LMRKSQILISSWF
- wherein the peptide reduces blood vessel formation in a cell, tissue or organ.
An isolated peptide or analog thereof comprising or consisting essentially of a sequence having at least 85% amino acid sequence identity to an amino acid sequence selected from the group consisting of:
- (SEQ ID NO:
- 2300)
- DEAH
- (SEQ ID NO:
- 2301)
- box polypeptide 8
- EIELVEEEPPF
- (SEQ ID NO:
- 2302)
- Caspase 10
- AEDLLSEEDPF
- (SEQ ID NO:
- 2303)
- CKIP-1
- TLDLIQEEDPS
- wherein the peptide reduces blood vessel formation in a cell, tissue or organ.
An isolated peptide or analog thereof comprising or consisting essentially of a sequence having at least 85% amino acid sequence identity to an amino acid sequence selected from the group consisting of:
- (SEQ ID NO:
- 2304)
- Collagen type IV, alpha6
- LPRFSTMPFIYCNINEVCHY
- fibril
- wherein the peptide reduces blood vessel formation in a cell, tissue or organ.
A pharmaceutical composition comprising an effective amount of an isolated peptide comprising an amino acid sequence shown in Table 1-10 or a peptide analog thereof in a pharmacologically acceptable excipient.
A method of modulating angiogenesis in a cell, tissue, or organ, the method comprising contacting the cell, tissue, or organ with an effective amount of an agent that binds CD36, CD47 or CXCR3.
Dependencies are inferred from the claim text.